Scalper1 News
Goldman Sachs analyst Salveen Richter launched coverage on a group of smid-cap biotech stocks Wednesday, rating the sector as neutral but flagging four stocks as worthy of investor attention. Here are his top picks: Bluebird Bio (BLUE): Richter gave this young biotech a buy rating at a price target of 165, a whopping 107% premium over Tuesday’s closing price. Bluebird stock suffered a setback earlier this month when its gene-therapy treatment Scalper1 News
Scalper1 News